Results 21 to 30 of about 630,325 (166)

Megalin Orchestrates FcRn Endocytosis and Trafficking [PDF]

open access: yes, 2022
The neonatal Fc receptor (FcRn) is highly expressed in the renal proximal tubule and is important for the reclamation of albumin by cellular transcytosis to prevent its loss in the urine. The initial event of this transcellular transport mechanism is the
Lea Maximiliane Klie   +9 more
core   +1 more source

Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans

open access: yesJCSM Rapid Communications, 2021
Background Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are lacking ...
Alyssa Marie M. Castillo   +17 more
doaj   +1 more source

Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis

open access: yesFrontiers in Immunology, 2023
BackgroundA series of clinical trials support the effectiveness of monoclonal antibodies for generalized myasthenia gravis (MG) compared to the placebo, but the priority among drugs remains unclear.
Huiru Chen   +10 more
doaj   +1 more source

Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling. [PDF]

open access: yes, 2021
Serum albumin shows slow clearance from circulation due to neonatal Fc receptor (FcRn)-mediated recycling and has been used for half-life extension. We report here fusions to a high-affinity DARPin, binding to Epithelial Cell Adhesion Molecule (EpCAM ...
Zangemeister-Wittke, Uwe   +11 more
core   +2 more sources

Characterization of Full‐Length Antibody Complexes Through HDX‐Mass Spectrometry Coupled With NMR Spectroscopy: New Insight Into Avelumab/PD‐L1 Interaction

open access: yesAngewandte Chemie, EarlyView.
Combining HDX‐MS and NMR enables the mapping of epitopes and paratopes in full‐length antibody complexes, revealing transient interactions and potential artifacts. ABSTRACT Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation,
Francesca Sacco   +13 more
wiley   +2 more sources

Targeting the Neonatal Fc Receptor, FcRn, to Treat Autoimmunity and Elucidation of Sites of FcRn Function [PDF]

open access: yes, 2020
The neonatal Fc receptor, FcRn, is expressed in many different cell types and serves several functions, some of which are cell type-specific. A function common to most cell types that express this receptor is salvage of IgG from cellular degradation ...
Challa, Dilip Kumar
core   +1 more source

Crystal structure of the compound UCB-FcRn-303 (R enantiomer) bound to FcRnECD.

open access: yes, 2018
(A) The protein crystallized as a dimer composed of two β2m (dark grey and green) and two α-chain (light grey and blue) molecules. (B) At the interface of β2m and the α-chain, UCB-FcRn-303 (grey) occupies a binding pocket with Glycine, Cysteine ...
Marta Westwood (485655)   +24 more
core   +1 more source

meyer-lab/FcRn-trafficking: Re-release to enable Zenodo DOI

open access: yes, 2019
Trafficking model of FcRn to explain the effects of failed release at the cell ...
Aaron Meyer
core   +1 more source

Characterization of the rabbit neonatal Fc receptor (FcRn) and analyzing the immunophenotype of the transgenic rabbits that overexpresses FcRn [PDF]

open access: yes, 2012
The neonatal Fc receptor (FcRn) regulates IgG and albumin homeostasis, mediates maternal IgG transport, takes an active role in phagocytosis, and delivers antigen for presentation.
Bosze, Z   +9 more
core   +3 more sources

Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16

open access: yesFrontiers in Immunology, 2021
The most challenging complication associated with Factor VIII (FVIII) replacement therapy is the development of neutralizing anti-drug antibodies, or inhibitors, which occur in 23-35% of severe (FVIII level <1%) hemophilia A (HA) patients and are a ...
H.A. Daniel Lagassé   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy